The FDA has approved the first blood test for Alzheimer's, allowing for earlier treatment with existing drugs. This innovative test measures protein ratios linked to the disease, promising better patient outcomes.
A groundbreaking study from Washington University reveals that new Alzheimer’s medications could extend patient independence by up to 13 months. Discover how these findings reshape treatment decisions.
Study shows that new Alzheimer's drugs lecanemab and donanemab can significantly extend the period of independent living for patients with early-stage Alzheimer's disease, highlighting potential benefits and risks.
